key: cord-0796555-ld40md1n
authors: Craigie, A.; McGregor, R.; Whitcombe, A.; Carlton, L.; Harte, D.; Sutherland, M.; Parry, M.; Smit, E.; McAuliffe, G.; Ussher, J.; Moreland, N.; Jack, S.; Upton, A.
title: SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020
date: 2020-10-23
journal: nan
DOI: 10.1101/2020.10.20.20215616
sha: 56d32b99cc5fa7a92ee1cf134f900be717cbe863
doc_id: 796555
cord_uid: ld40md1n

Background: During New Zealand's first outbreak in early 2020 the Southern Region had the highest per capita SARS-CoV-2 infection rate. PCR testing was initially limited by a narrow case definition and limited laboratory capacity, so cases may have been missed. Objectives: To evaluate the Abbott SARS-CoV-2 IgG nucleocapsid assay, alongside spike-based assays, and to determine the frequency of antibodies among PCR-confirmed and probable cases, contacts, and higher risk individuals in the Southern Region of NZ. Study design: Pre-pandemic sera (n=300) were used to establish assay specificity and sera from PCR-confirmed SARS-CoV-2 patients (n=78) to establish sensitivity. For prevalence analysis, all samples (n=1214) were tested on the Abbott assay, and all PCR-confirmed cases (n=78), probable cases (n=9), and higher risk individuals with grey-zone (n=14) or positive results (n=11) were tested on four additional SARS-CoV-2 serological assays. Results: The median time from infection onset to serum collection for PCR-confirmed cases was 14 weeks (range 11-17 weeks). The Abbott assay demonstrated a specificity of 99.7% (95% CI, 98.2%-99.99%) and a sensitivity of 76.9% (95% CI, 66.0%-85.7%). Spike-based assays demonstrated superior sensitivity ranging 89.7-94.9%. Nine previously undiagnosed sero-positive individuals were identified, and all had epidemiological risk factors. Conclusions: Spike-based assays demonstrated higher sensitivity than the Abbott IgG assay, likely due to temporal differences in antibody persistence. No unexpected SARS-CoV-2 infections were found in the Southern region of NZ, supporting the elimination status of the country at the time this study was conducted.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it 53 causes, COVID-19, were first detected in Wuhan, China in December 2019 [1] . By 22 54 May 2020, there were nearly 5 million confirmed COVID-19 cases worldwide, with 55 ~336000 deaths [2] . During New Zealand's (NZ) first outbreak (28 February to 22 May 56 2020) a total of 1154 PCR-confirmed and 350 probable cases were identified, with 22 57 COVID-19 related deaths [3] . 58 This serological study is focused on the Southern District Health Board (SDHB) region 59 in NZ, which had the largest number of COVID-19 cases per capita during NZ's first 60 outbreak (216 total cases; ~66/100,000 population), significantly higher than the 61 national average (~30/100,000) [3] . This region also includes the tourism hub of 62 Queenstown, where community transmission took place. PCR testing for SARS-CoV-63 2 was initially restricted in NZ due to a narrow case definition and limited access to 64 diagnostic reagents. lockdown period (alert level three and four, between 23 rd March to May 12 th 2020) 99 (Table 1) . Blood samples were collected between 4 th June and 4 th August 2020. 100 The severity of COVID-19 in the PCR-confirmed group was classified on the basis of 101 their symptoms and the level of hospital care provided: 1asymptomatic to mild cold-102 like symptoms (n=35); 2moderate: cough, fever and chills (n=39); 3moderately 103 severe: admitted for assessment (n=3); 4severe: admitted and given supplemental 104 oxygen therapy (n=1); 5critical: admitted to ICU (n=0).

To determine assay specificity, 300 de-identified antenatal sera collected from early-106 mid 2019 (pre-pandemic), were used (after being stored at -20 o C for up to 12 months).

Serological assays 108 The assays utilised are summarised in Table 2 . The primary assay was the Abbott 109 Architect SARS-CoV-2 IgG chemiluminescent microparticle immunoassay (CMIA) 110 (Abbott, Chicago, USA). Samples were analysed on the Abbott Architect i2000SR 111 Immunoassay Analyzer following manufacturer's instructions.

The in-house two-step ELISA was adapted from published protocols [7] as described 113 [8]. In step one serum diluted 1:100 was screened against RBD, with IgG binding 114 detected with a peroxidase-labelled anti-human IgG secondary. Samples with an optical 115 density (OD, 450-570nm) above the cut-off (>0.2) were titrated in a 3-fold dilution 116 series against the S protein in step two and considered positive if OD>0.2 in at least 117 two consecutive wells in the confirmatory S protein ELISA. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10. 1101 measures the presence of neutralising antibodies (NAbs) that are capable of blocking 123 the interaction between RBD and hACE2 [9] and was performed according to 124 manufacturer's instructions. Samples with percentage inhibition ≥20% were defined as 125 having neutralising antibodies.

To assess cross-reactivity of antenatal sera with other human coronaviruses (HCoV), 127 ELISA were performed using S1 antigens from the HKU1, NL63, and SARS-CoV-2 128 (Sino Biological, Beijing, China) at 1:300 sera dilution as described [8] .

Testing protocol 130 The antenatal samples and serum from PCR-confirmed and probable cases were tested 131 on all five assays. All sera from the higher risk group (n=1127) were tested on the 132 Abbott assay. Samples from the higher risk group that classified as positive (≥1.4 S/C), 133 or as negative but ≥ 0.5 S/C (i.e. 0.5-1.39 S/C, defined as the grey-zone on the basis of 134 a receiver operating characteristic (ROC) curve) were tested on all assays (n=25).

Statistical analysis was performed using Prism 8 (GraphPad) or R (version 3.6.3) within 137 R Studio (version 1.2.5033); a P-value of ≤0.05 was considered statistically significant.

To assess sensitivity, we chose the PCR results as gold standard. Equivocal results were 139 considered negative for the statistical analyses. For the higher risk group, true sero- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10. 1101 seven were negative by all assays, and the Abbott assay raw values of these ranged from 191 0.01 -0.04 S/C, suggesting that these were unlikely to have had COVID-19 infection.

Using a cohort of PCR-confirmed cases to assess sensitivity, we found suboptimal 

In our hands, the Abbott assay specificity was 99.7% (95% CI, 98.2%-99.99%), 205 comparable to the manufacturer's claim (99.6%). However, given the very low 206 prevalence of COVID-19 infection in NZ, the positive-predictive value will be 207 relatively low. Thus, we suggest an orthogonal testing algorithm (a second assay, using 208 a different target) as a supplemental assay before reporting results as true positives.

S protein is the main target for SARS-CoV-2 NAbs [15] . In this study NAbs were 210 measured using a sVNT [9] with 88.5% of the PCR-confirmed cases having detectable 211 NAbs 11-17 weeks post-infection, with lower NAbs among those with mild symptoms.

A decline in NAb levels has been noted in recent reports [13] , but further studies are 213 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. risks; further testing of NZ's remaining 341 probable cases may be warranted.

Our study has some limitations. Firstly, the delay in specimen collection after the 248 outbreak likely had an impact on the Abbott assay sensitivity. We cannot be certain that 249 undiagnosed cases were not missed using the Abbott assay as our screening test.

However, every effort was made to mitigate against this by lowering the cut-off for the 251 initial Abbott screening assay. Lastly, it is important to note that this is not a sero-252 prevalence study. Participants who self-identified as higher risk were actively recruited, 253 therefore the sero-positivity rate calculated in this group in the SDHB region cannot be 254 extrapolated to the general population.

In conclusion, our study shows that the COVID-19 outbreak in the SDHB region in 257 early 2020 was largely confined to the PCR-confirmed cases and those identified as at 258 higher risk due to recent travel and/or close contact with a known case. We found little 259 evidence of undetected infection among the individuals in the SDHB region who were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10. 1101 sensitivity of the assays investigated, likely impacted by the delay in serum collection.

Whilst this may lead to missed cases, the utility of a high throughput system for large 264 scale testing does, to a degree, offset this significant limitation, especially when 265 combined with secondary S protein assays of higher sensitivity. When designing a 266 SARS-CoV-2 serological assay algorithm, the purpose of testing is a major 267 consideration, with different assay combinations suitable for high-throughput sero- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 

Jiang is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10. 1101 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10. 1101 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10. 1101 

Longitudinal evaluation and decline of antibody responses 356 in SARS-CoV-2 infection. medRxiv

Humoral Response Dynamics Following Infection with 360 SARS-CoV-2. medRxiv

SARS-CoV-2 infection induces robust, neutralizing 364 antibody responses that are stable for at least three months. medRxiv

Estimating prevalence from the results of a 367 screening test

Assay SARS-CoV-2 antigen Sensitivity (%) Specificity (%)

IgG (using manufacturer cut-off of ≥1.40) N protein 76

IgG (using revised cut-off of ≥0.50) N protein 94

Wantai SARS-CoV-2 total antibody ELISA RBD/S protein